摘要
新型冠状病毒肺炎(COVID-19)属于中医疫病范畴,病因为感受疫戾之气,病位初期在上焦。中医认为鼻为肺之窍,为呼吸之门户,清代外治医家吴尚先在《理瀹骈文》论述“大凡上焦之病,以药研细末,㗜鼻取嚏发散为第一捷法”。而我国古代医家在千百年来同疫病的斗争中,探索并发扬了中医纳鼻法。清开灵为清热解毒基础方,现代研究明确了其在上呼吸道感染中的治疗作用。该文基于中医纳鼻法,以清开灵制剂为例,研究其制备成鼻用制剂应用于新型冠状病毒肺炎的可行性,一方面有助于快速研制抗2019新型冠状病毒的清开灵鼻用制剂,另一方面可拓宽中药治疗疫病的新思路,充分发挥中药治疗疫病的优势。
Coronavirus disease-2019(COVID-19)belongs to the epidemic diseases of traditional Chinese medicine(TCM),which is infected by the air with disease and the initial stage of the disease is in upper energizer.TCM holds that the nose is the orifice of the lung and the gateway of the breath.WU Shang-xian,the famous external doctor in Qing dynasty,discussed in Liyue Pianwen that"for the disease in upper energizer,the most effective method is to use the medicine powder via nasal administration and sneeze to disperse".For thousands of years,ancient Chinese medical practitioners had explored and developed the TCM nasal administration method in the struggle against epidemics.Qingkailing is the basic formula for heat-clearing and detoxifying,and researches have clarified its therapeutic effect on upper respiratory tract infections.Therefore,based on TCM nasal administration,this article took Qingkailing as an example to study the feasibility of its nasal preparations for the treatment of COVID-19.On the one hand,it is helpful for the rapid development of Qingkailing nasal preparations for COVID-19.On the other hand,it can broaden the new thinking of TCM in treating epidemic diseases,and give full play to the advantages of TCM in treating epidemic diseases.
作者
李楠
张艺
黄潇
刘紫轩
张羽璐
向燕
LI Nan;ZHANG Yi;HUANG Xiao;LIU Zi-xuan;ZHANG Yu-lu;XIANG Yan(Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China;Shenwei Pharmaceutical Group Co.Ltd.,Shijiazhuang 051430,China)
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2020年第19期68-75,共8页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家重点研发计划“中医药现代化研究”重点专项(2017YFC1703900)
国家自然科学基金项目(81673615)
成都中医药大学“杏林学者”学科人才科研提升计划新冠病毒应急专项(XGZX2010)。
